Close Menu

NEW YORK (GenomeWeb) – Genomic Health said today that it has signed a multi-year research collaboration agreement with Janssen Pharmaceuticals in which the companies will evaluate Genomic Health's Oncotype DX Genomic Prostate Score as a predictor of response to prostate cancer drugs in Janssen's pipeline.

Under the terms of the agreement, Genomic Health will test samples from studies Janssen is conducting to examine the association of GPS results with clinical outcomes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.